Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical Inc. has demonstrated robust revenue growth, reporting a 31% year-over-year increase in net revenue to $209.4 million, exceeding both internal forecasts and market consensus. The company has also shown significant strength in its product line, particularly with Jornay, which experienced a 28.2% sequential revenue growth, driven by a notable 20% year-over-year increase in total prescriptions. The updated guidance for 2025 reflects heightened expectations, with projected top-line revenue increased to between $745 million and $760 million, highlighting ongoing market share gains and promising expansion opportunities within the adult segment.

Bears say

Collegium Pharmaceutical Inc. faces significant challenges that contribute to a negative outlook for its stock, primarily due to declining prescription volumes for key products such as Xtampza ER, Belbuca, and Nucynta, alongside the potential for generic competition disrupting their market positions. Although the company reported an operating cash flow of $78.4 million for the quarter and aims to reduce net leverage below 1.0x by year-end 2025, concerns remain regarding its ability to maintain sales levels and navigate the complexities of reimbursement dynamics in a competitive landscape. Additionally, the reliance on third-party partnerships for product commercialization introduces execution risks that could further impair profitability and regulatory compliance.

Collegium Pharmaceutical (COLL) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 5 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.